Semaglutide
5 mg
$39.00
Retatrutide is a triple agonist acting on GLP-1, GIP and glucagon receptors, supplied as a lyophilized powder vial paired with a separate vial of bacteriostatic water for reconstitution. Shipped with full cold-chain handling.
For use by licensed and trained professionals only, operating within their applicable regulations. Not evaluated by the FDA.
Retatrutide is a triple agonist acting on GLP-1, GIP and glucagon receptors, supplied as a lyophilized powder vial paired with a separate vial of bacteriostatic water for reconstitution. Shipped with full cold-chain handling.
Supplied to licensed and trained professionals only, operating within their applicable regulations. Keep refrigerated at 2–8 °C both before and after reconstitution; do not freeze. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
| Available sizes | 5 mg — $69.00 · 10 mg — $99.00 · 20 mg — $149.00 · 30 mg — $199.00 |
| Form | Lyophilized powder + BAC water vial |
| Molecular weight | 4731.3 g/mol |
| CAS | 2381089-83-2 |
| Sequence length | 39 |
| Storage — sealed | −20 °C, protected from light |
| Storage — reconstituted | 2–8 °C, use within 14 days |
| Ships from | Chicago, IL |
| SKU | GLP-RETA |
Research summary — for laboratory and research use only. Not medical advice, not a dosing recommendation, and not an FDA evaluation of safety or efficacy.
Retatrutide is an investigational triple-hormone receptor agonist developed by Eli Lilly, currently in the TRIUMPH Phase 3 clinical-trial program. As of mid-2026 it is not FDA-approved; Lilly has indicated it plans to file for regulatory approval following completion of Phase 3 trials.
Retatrutide is engineered to activate three receptors in a single molecule — GLP-1, GIP (glucose-dependent insulinotropic polypeptide) and glucagon — combining incretin-driven appetite suppression with glucagon-receptor activity that increases energy expenditure, a mechanistic combination that published Phase 2 data associated with weight-loss magnitudes larger than single-agonist GLP-1 therapies.
Lilly's ongoing Phase 3 program is studying retatrutide across obesity, obesity with knee osteoarthritis, obesity with obstructive sleep apnea, and related indications.
As one of the first agents to combine GLP-1, GIP and glucagon receptor activity, it is a reference compound in research comparing single- versus multi-receptor incretin strategies.
Published Phase 2 data in type 2 diabetes has also been examined alongside the weight-management program.
Supplied to licensed and trained professionals only, operating within their applicable regulations. Keep refrigerated at 2–8 °C both before and after reconstitution; do not freeze. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
No — it remains an investigational drug in Lilly's Phase 3 program as of 2026, not yet available as an approved prescription product. It is supplied here for research use by qualified professionals only.
Further reading: for the published preclinical and clinical literature on Retatrutide, search PubMed. We link to the search rather than cherry-picked citations so you can review the current, full body of literature yourself.